News

Update on Regulatory Review of NEZGLYAL® (leriglitazone) in the EU

2024-05-31 Update on Regulatory Review of NEZGLYAL® (leriglitazone) in the EU Despite CHMP upholding the negative opinion for treatment of cerebral  adrenoleukodystrophy (cALD) the companies remain committed to the continued development of NEZGLYAL® for cALD Barcelona, Spain and Düsseldorf, Germany – 31 May, 2024 – Minoryx Therapeutics, a late stage biotech company focused on the development of therapies…

Read more

Update on Regulatory Review of leriglitazone in the EU

2024-01-26 A re-examination for cerebral adrenoleukodystrophy (cALD) will be requested following the negative CHMP opinion on X-linked adrenoleukodystrophy (X-ALD) Barcelona, Spain and Düsseldorf, Germany – 26 January, 2024 – Minoryx Therapeutics, a late stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders and Neuraxpharm Group (Neuraxpharm), a leading European…

Read more

Update — Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference

05/31/2023 IRVINE, Calif., May 31, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate at the Jefferies Healthcare Conference. Jefferies Healthcare ConferenceDate: Wednesday, June 7, 2023Location:…

Read more

The Lancet Neurology publishes results from Minoryx Therapeutics Phase 2/3 ADVANCE clinical trial of leriglitazone in X-linked Adrenoleukodystrophy

Leriglitazone was well tolerated, and significant benefit was shown through clinically meaningful myelopathy endpoints and reduced progression of cerebral lesions Mataró, Barcelona, Spain, January 20, 2023 – Minoryx Therapeutics (“Minoryx”), a Phase 3 clinical stage biotech company focused on the development of differentiating treatment options in orphan central nervous system (CNS) disorders, today announces that data from its Phase 2/3…

Read more

Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences

November 2, 2023 IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate in the following investor conferences. Jefferies London Healthcare ConferenceDate: Tuesday,…

Read more

Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences

August 29, 2023 IRVINE, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate at the upcoming healthcare investor conferences. Citi BioPharma ConferenceDate: Wednesday,…

Read more